Skip to main content

Shares in Decode Slide 9.8 Percent on News of Poor Q4 Earnings, Revenue Growth

NEW YORK, March 4 (GenomeWeb News) - Shares in Decode Genetics were down 9.76 percent, or $.61, at $5.64 in mid-afternoon trading after the company posted a slight decrease in fourth-quarter revenues atop nearly doubled net losses.


As GenomeWeb News reported this morning, total revenues for the three-month period ended Dec. 31, 2004, fell to $11.2 million from $11.7 million during the same period a year ago.


R&D expenses increased to $8.7 million from $5.8 million during the fourth quarter of 2003. This increase was mainly due to costs associated with clinical trials for two compounds, according to Decode.


Decode's net loss for the quarter swelled to $19.4 million, or $.36 per share, from $10.6 million, or $.20 per share, during the same period in 2003. This steep increase resulted from costs of clinical trials, debt service, and the impact of foreign exchange fluctuations, according to the company.


As of Dec. 31, 2004, Decode had $198.3 million in cash and investments, including restricted cash, cash equivalents, marketable securities, and other investments.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.